| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2025 | 41 | 1.390 |
Why?
|
| HIV-1 | 16 | 2018 | 723 | 1.280 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2022 | 90 | 1.010 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2025 | 48 | 0.890 |
Why?
|
| Virion | 1 | 2025 | 121 | 0.870 |
Why?
|
| HIV Infections | 13 | 2018 | 972 | 0.830 |
Why?
|
| Influenza, Human | 3 | 2022 | 208 | 0.690 |
Why?
|
| Herpesvirus 4, Human | 6 | 2018 | 196 | 0.550 |
Why?
|
| Cytidine Deaminase | 6 | 2018 | 86 | 0.540 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 58 | 0.450 |
Why?
|
| Electron Microscope Tomography | 2 | 2025 | 15 | 0.420 |
Why?
|
| Infectious Mononucleosis | 4 | 2016 | 34 | 0.370 |
Why?
|
| Cryoelectron Microscopy | 2 | 2025 | 200 | 0.360 |
Why?
|
| DNA, Single-Stranded | 3 | 2018 | 106 | 0.360 |
Why?
|
| Virus Replication | 5 | 2016 | 321 | 0.350 |
Why?
|
| Protein Binding | 10 | 2025 | 1603 | 0.340 |
Why?
|
| Antibodies, Viral | 4 | 2021 | 325 | 0.340 |
Why?
|
| Antibodies, Neutralizing | 4 | 2021 | 208 | 0.330 |
Why?
|
| DNA, Viral | 4 | 2016 | 232 | 0.330 |
Why?
|
| Proteins | 4 | 2018 | 753 | 0.320 |
Why?
|
| Drug Resistance, Viral | 3 | 2022 | 157 | 0.320 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 19 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 3 | 2016 | 77 | 0.300 |
Why?
|
| Viral Matrix Proteins | 3 | 2016 | 50 | 0.290 |
Why?
|
| Viral Proteins | 4 | 2022 | 263 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 545 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2015 | 677 | 0.280 |
Why?
|
| Viral Tropism | 2 | 2018 | 53 | 0.270 |
Why?
|
| Genetic Variation | 4 | 2018 | 384 | 0.260 |
Why?
|
| Antiviral Agents | 4 | 2023 | 322 | 0.260 |
Why?
|
| Humans | 37 | 2025 | 63535 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 103 | 0.220 |
Why?
|
| Serine Endopeptidases | 2 | 2022 | 84 | 0.220 |
Why?
|
| Mutation | 7 | 2022 | 2615 | 0.210 |
Why?
|
| Catalytic Domain | 2 | 2017 | 198 | 0.200 |
Why?
|
| Influenza A virus | 2 | 2022 | 123 | 0.200 |
Why?
|
| Neuraminidase | 2 | 2022 | 42 | 0.190 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 11 | 0.190 |
Why?
|
| Gene Products, vpr | 1 | 2002 | 7 | 0.190 |
Why?
|
| Monocytes | 2 | 2016 | 353 | 0.190 |
Why?
|
| Oseltamivir | 1 | 2022 | 35 | 0.180 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 5 | 0.170 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 37 | 0.170 |
Why?
|
| Darunavir | 1 | 2021 | 30 | 0.170 |
Why?
|
| Epitopes | 2 | 2021 | 290 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2021 | 102 | 0.160 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 103 | 0.160 |
Why?
|
| Phylogeny | 6 | 2018 | 378 | 0.160 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 669 | 0.160 |
Why?
|
| Genome, Viral | 2 | 2018 | 136 | 0.160 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 58 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 76 | 0.160 |
Why?
|
| Apoptosis | 2 | 2021 | 1080 | 0.150 |
Why?
|
| Models, Molecular | 7 | 2019 | 1151 | 0.150 |
Why?
|
| RNA, Viral | 3 | 2016 | 276 | 0.150 |
Why?
|
| Amino Acid Sequence | 8 | 2021 | 1590 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2018 | 182 | 0.140 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 460 | 0.140 |
Why?
|
| Cytidine | 1 | 2017 | 15 | 0.130 |
Why?
|
| CD4 Antigens | 1 | 2018 | 149 | 0.130 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2005 | 24 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2018 | 133 | 0.120 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 13 | 0.120 |
Why?
|
| Macrophages | 2 | 2018 | 1041 | 0.120 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2022 | 45 | 0.110 |
Why?
|
| Virus Latency | 1 | 2015 | 32 | 0.110 |
Why?
|
| Viral Load | 5 | 2016 | 231 | 0.110 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 572 | 0.110 |
Why?
|
| RNA | 1 | 2018 | 426 | 0.110 |
Why?
|
| Neutralization Tests | 4 | 2019 | 127 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 248 | 0.110 |
Why?
|
| Mothers | 3 | 2015 | 276 | 0.110 |
Why?
|
| Oropharynx | 1 | 2014 | 12 | 0.110 |
Why?
|
| Cytosine Deaminase | 1 | 2013 | 6 | 0.100 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 322 | 0.100 |
Why?
|
| Crystallography, X-Ray | 4 | 2017 | 432 | 0.100 |
Why?
|
| Infant | 6 | 2016 | 1654 | 0.100 |
Why?
|
| Genotype | 2 | 2018 | 664 | 0.100 |
Why?
|
| Transcriptome | 1 | 2015 | 386 | 0.090 |
Why?
|
| A549 Cells | 2 | 2022 | 39 | 0.090 |
Why?
|
| Adult | 8 | 2021 | 16896 | 0.090 |
Why?
|
| Substrate Specificity | 3 | 2018 | 339 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 58 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 30 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1993 | 0.090 |
Why?
|
| Protein Conformation | 3 | 2021 | 780 | 0.080 |
Why?
|
| Gene Products, vif | 2 | 2007 | 9 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 301 | 0.080 |
Why?
|
| Stavudine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Nevirapine | 1 | 2010 | 8 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 417 | 0.080 |
Why?
|
| Human Growth Hormone | 1 | 2010 | 19 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 149 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 373 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1556 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 347 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 287 | 0.070 |
Why?
|
| Influenza Vaccines | 2 | 2021 | 99 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2003 | 642 | 0.070 |
Why?
|
| Child | 3 | 2010 | 4541 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 154 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2007 | 220 | 0.070 |
Why?
|
| Cryopreservation | 1 | 2008 | 30 | 0.070 |
Why?
|
| HIV Antigens | 1 | 2008 | 18 | 0.070 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Time Factors | 3 | 2014 | 3710 | 0.070 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2022 | 112 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 61 | 0.070 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 38 | 0.070 |
Why?
|
| Cell Line | 5 | 2018 | 2041 | 0.070 |
Why?
|
| Viral Envelope Proteins | 2 | 2005 | 103 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 45 | 0.070 |
Why?
|
| Acute Disease | 3 | 2016 | 669 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 262 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 66 | 0.060 |
Why?
|
| HIV Long-Term Survivors | 2 | 2005 | 8 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 91 | 0.060 |
Why?
|
| Female | 9 | 2021 | 32947 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 373 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2021 | 385 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 311 | 0.060 |
Why?
|
| APOBEC-3G Deaminase | 3 | 2012 | 21 | 0.060 |
Why?
|
| Male | 7 | 2021 | 29938 | 0.060 |
Why?
|
| Monkey Diseases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Callithrix | 1 | 2005 | 21 | 0.060 |
Why?
|
| Adolescent | 3 | 2015 | 6258 | 0.060 |
Why?
|
| Protein Structure, Secondary | 2 | 2017 | 260 | 0.060 |
Why?
|
| Alleles | 2 | 2007 | 447 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 674 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 96 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1665 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2004 | 67 | 0.050 |
Why?
|
| Lung | 3 | 2023 | 958 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2018 | 176 | 0.050 |
Why?
|
| Binding Sites | 2 | 2018 | 906 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2016 | 1999 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 94 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2016 | 299 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2018 | 153 | 0.050 |
Why?
|
| Genes, vpr | 1 | 2002 | 4 | 0.050 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pneumonia | 1 | 2005 | 290 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2002 | 97 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2009 | 3296 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 190 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 490 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2005 | 628 | 0.040 |
Why?
|
| Gene Expression | 2 | 2018 | 843 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 243 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2023 | 221 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 135 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2012 | 100 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2012 | 2166 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 863 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 129 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 120 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 95 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2021 | 612 | 0.040 |
Why?
|
| Animals | 6 | 2023 | 20716 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2012 | 85 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 2012 | 117 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 1363 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2012 | 147 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2019 | 22 | 0.040 |
Why?
|
| Reverse Genetics | 1 | 2019 | 10 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Proviruses | 1 | 2018 | 27 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 84 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 174 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 330 | 0.030 |
Why?
|
| Deamination | 1 | 2017 | 11 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 238 | 0.030 |
Why?
|
| Convalescence | 1 | 2016 | 18 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 922 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 78 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2018 | 146 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 458 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 363 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 149 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 707 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 664 | 0.030 |
Why?
|
| Genes, env | 1 | 2015 | 16 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 71 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 410 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 10864 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 354 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 265 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 114 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 145 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Genomics | 1 | 2018 | 375 | 0.030 |
Why?
|
| Zinc | 1 | 2015 | 92 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 1331 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 695 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1120 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 751 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 262 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 641 | 0.020 |
Why?
|
| Catalysis | 1 | 2013 | 162 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2015 | 1515 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1470 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5630 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1259 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 2572 | 0.020 |
Why?
|
| AIDS Vaccines | 1 | 2012 | 71 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2012 | 18 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 183 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 131 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 381 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2010 | 59 | 0.020 |
Why?
|
| Lamivudine | 1 | 2010 | 7 | 0.020 |
Why?
|
| Directly Observed Therapy | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cambodia | 1 | 2010 | 27 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 866 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 93 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 622 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 113 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 373 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2464 | 0.020 |
Why?
|
| Humidity | 1 | 2008 | 12 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 574 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 132 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2007 | 29 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 239 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2007 | 137 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 536 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 1015 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 50 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 292 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1092 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 111 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 227 | 0.010 |
Why?
|
| Carboxypeptidases | 1 | 2003 | 8 | 0.010 |
Why?
|
| Giant Cells | 1 | 2003 | 15 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 218 | 0.010 |
Why?
|
| Vero Cells | 1 | 2003 | 80 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 186 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4713 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2003 | 73 | 0.010 |
Why?
|
| Myocardium | 1 | 2005 | 287 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 180 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 287 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2003 | 19 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 73 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 883 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 182 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2003 | 39 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 452 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1284 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 311 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2003 | 237 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1991 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1146 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 778 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2196 | 0.010 |
Why?
|